BCM
RIGL icon

Bridgeway Capital Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Bridgeway Capital Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.86M Buy
+124,184
New +$3.83M 0.09% 306
2026
Q1 		– Sell
-12,520
Closed -$536K – 1306
2025
Q4 		$536K Sell
12,520
-9,950
-44% -$375K 0.01% 809
2025
Q3 		$637K Sell
22,470
-12,500
-36% -$374K 0.01% 761
2025
Q2 		$655K Sell
34,970
-12,500
-26% -$237K 0.02% 725
2025
Q1 		$854K Sell
47,470
-15,400
-24% -$312K 0.02% 667
2024
Q4 		$1.06M Sell
62,870
-1,670
-3% -$32K 0.02% 656
2024
Q3 		$1.04M Hold
64,540
– – 0.02% 673
2024
Q2 		$531K Buy
64,540
+5,000
+8% +$52.3K 0.01% 845
2024
Q1 		$881K Sell
59,540
-7,500
-11% -$101K 0.02% 772
2023
Q4 		$972K Buy
67,040
+7,620
+13% +$77.9K 0.02% 768
2023
Q3 		$642K Buy
59,420
+21,920
+58% +$264K 0.02% 820
2023
Q2 		$484K Buy
37,500
+11,500
+44% +$155K 0.01% 914
2023
Q1 		$343K Sell
26,000
-6,500
-20% -$103K 0.01% 976
2022
Q4 		$488K Hold
32,500
– – 0.01% 885
2022
Q3 		$384K Buy
+32,500
New +$440K 0.01% 963
2017
Q4 		– Sell
-15,780
Closed -$401K – 1438
2017
Q3 		$401K Hold
15,780
– – ﹤0.01% 1145
2017
Q2 		$431K Hold
15,780
– – 0.01% 1131
2017
Q1 		$522K Hold
15,780
– – 0.01% 1061
2016
Q4 		$376K Sell
15,780
-4,000
-20% -$115K ﹤0.01% 1174
2016
Q3 		$726K Buy
19,780
+780
+4% +$22.4K 0.01% 927
2016
Q2 		$424K Hold
19,000
– – 0.01% 1113
2016
Q1 		$395K Sell
19,000
-530
-3% -$13.1K 0.01% 1133
2015
Q4 		$592K Sell
19,530
-3,650
-16% -$111K 0.01% 987
2015
Q3 		$573K Buy
23,180
+3,650
+19% +$109K 0.01% 960
2015
Q2 		$627K Sell
19,530
-230
-1% -$8.79K 0.01% 963
2015
Q1 		$705K Hold
19,760
– – 0.01% 942
2014
Q4 		$449K Sell
19,760
-9,490
-32% -$192K 0.01% 1114
2014
Q3 		$567K Buy
29,250
+1,640
+6% +$46.3K 0.01% 1015
2014
Q2 		$1M Buy
27,610
+13,270
+93% +$451K 0.03% 776
2014
Q1 		$556K Buy
+14,340
New +$511K 0.02% 1024

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bridgeway Capital Management's RIGL Position: Q2 2026 in Review

Bridgeway Capital Management opened a new position in Rigel Pharmaceuticals (RIGL) in Q2 2026: 124,184 shares worth $4.86M. The stake represents 0.09% of the portfolio and ranks #306 among its holdings. This is a return to the name: Bridgeway Capital Management previously reported a position in RIGL as recently as Q4 2025.

Bridgeway Capital Management first reported a position in RIGL in Q1 2014 and has held it in 30 quarters since. 156 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • Bridgeway Capital Management held 124,184 shares of Rigel Pharmaceuticals worth $4.86M as of Q2 2026.
  • Rigel Pharmaceuticals was a new Bridgeway Capital Management position in Q2 2026.
  • Rigel Pharmaceuticals made up 0.09% of Bridgeway Capital Management's portfolio in Q2 2026, its #306 holding.
  • Bridgeway Capital Management first reported a position in Rigel Pharmaceuticals in Q1 2014 and has held it in 30 quarters since.
  • 156 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.